News | ESC | July 21, 2020

European Society of Cardiology Announces Late-Breaking Study Presentations at its 2020 Virtual Congress

The European Society of Cardiology (ESC) will host several Hot Lines sessions that will include some of the latest clinical science presentations in cardiology at the 2020 annual congress digital meeting. The meeting has gone virtual due to the ongoing pandemic. 

The European Society of Cardiology (ESC) will host several Hot Lines sessions that will include some of the latest clinical science presentations in cardiology at the 2020 annual congress digital meeting. The meeting has gone virtual due to the ongoing pandemic. 

The congress is planned for Saturday, Aug. 29, through Tuesday Sept. 1, 2020. Read more on ECS's move to a digital meeting.

ESC said the event will include live presentations and panel discussions. To find out more, visit the event website at https://www.escardio.org/Congresses-&-Events/ESC-Congress

Hot Line sessions below are all in Central European Summer Time (CEST):

Saturday, Aug. 29
   • Hot Line 1: EMPEROR-Reduced: Empagliflozin in Heart Failure With a Reduced Ejection Fraction, With and Without Diabetes. 14:30 - 15:00
   • Hot Line 2: EXPLORER-HCM: Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy. 15:30 - 16:00
   • Hot Line 3: EAST – AFNET 4: Effects of Early Rhythm Control Therapy in Patients with Atrial Fibrillation. 17:00 - 17:30

 

Sunday, Aug. 30
   • Hot Line 4: ATPCI - Trimetazidine in Angina Patients with Recent Successful Percutaneous Coronary Intervention: a Randomized, Double-Blind, Placebo-Controlled Trial. 14:00 - 14:30
   • Hot Line 5: POPULAR TAVI -Aspirin With or Without Clopidogrel. 14:30 - 15:00
   • Hot Line 6: PARALLAX: Sacubitril/Valsartan versus Individualized RAAS Blockade in Patients with HFpEF. 16:30 - 17:00

 

 

Monday, Aug. 31
   • Hot Line 7: LoDoCo2 Low-Dose Colchicine in Coronary Disease. 14:00 - 14:30
   • Hot Line 8: HOME-PE - Hospitalisation or Outpatient Management of PE Patients - HESTIA vs. Simplified PESI. 14:30 - 15:00
   • Hot Line 9: BPLTTC - Blood Pressure Lowering for Prevention of Cardiovascular Events across Different Levels of Blood Pressure. 16:30 - 17:00

 

Tuesday, Sept. 1
   • Hot Line 10: BRACE CORONA: Continuing vs. Suspending ACE Inhibitors and ARBs in COVID-19. 14:00 - 14:30
   • Hot Line 11: IMPACT-Afib Implementation of Stroke Prevention in Atrial Fibrillation. 14:30 - 15:00
   • Hot Line 12: REALITY - A Trial of Transfusion Strategies for Myocardial Infarction and Anemia. 16:30 - 17:00

 

Other ESC Clinical Studies

Study Shows Severe Fainting Can Be Treated with Cardiac Pacing Supported by Closed Loop Stimulation

Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study
 

Read the article Highlights From the 2019 ESC Congress.
 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now